πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Cellectar Biosciences, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Alector, Inc.

Alector, Inc. logo
Market Cap: Medium
Employees: Low

AL001, AL101, AL002, AL003, AL044

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.

Tags: Alzheimer's, Parkinson's, biopharmaceutical, clinical trials, neurodegeneration, therapies

Symbol: ALEC

Recent Price: $1.72

Industry: Biotechnology

CEO: Dr. Arnon Rosenthal Ph.D.

Sector: Healthcare

Employees: 245

Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 415 231 5660

Leadership

  • Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
  • Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
  • Marc Grasso, M.D., Chief Financial Officer
  • Gary Romano, M.D., Ph.D., Chief Medical Officer
  • Danielle Pasqualone, Ph.D., J.D., General Counsel
  • Clare Hunt, M.B.A., Chief People Officer
  • Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
  • Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
  • Norah Conway, Senior Vice President, Portfolio and Program Management
  • Neil Berkley, M.S., M.B.A., Chief Business Officer
  • Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
  • Elizabeth Garofalo, M.D., Board Member
  • Paula Hammond, Ph.D., Board Member
  • Richard H. Scheller, Ph.D., Board Member
  • David Wehner, Board Member
  • Kristine Yaffe, M.D., Board Member
  • Errol De Souza, Ph.D., Board Member
  • Mark Altmeyer, M.B.A., Board Member

Last updated: 2024-12-31

Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CY6463

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious CNS diseases, with products like CY6463 for mitochondrial encephalomyopathy and Alzheimer's disease.

Tags: CNS diseases, CY6463, biopharmaceutical, clinical-stage, therapy development

Symbol: CYCN

Recent Price: $3.45

Industry: Biotechnology

CEO: Dr. Regina Graul Ph.D.

Sector: Healthcare

Employees: 1

Address: 245 First Street, Cambridge, MA 02142

Phone: 857 327 8778

Last updated: 2024-12-31

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELI-002

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.

Tags: Biotechnology, Cancer Treatment, Clinical-stage, Immunotherapy, Vaccines

Symbol: ELTX

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert T. Connelly

Sector: Healthcare

Employees: 32

Address: 451 D Street, Boston, MA 02210

Phone: 857-209-0050

Last updated: 2024-12-31

PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. logo
Market Cap: Lowest
Employees: Lowest

Cell-in-a-Box

Pharma Cyte Biotech, Inc. is a biotechnology company focused on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites. Their therapies are based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology, used for treating various cancers and diabetes.

Tags: Cell-in-a-Box, biotechnology, cancer, cannabis plant, cellular therapies, diabetes, insulin-dependent diabetes, live cell encapsulation, pancreatic cancer

Symbol: PMCB

Recent Price: $1.55

Industry: Biotechnology

CEO: Mr. Joshua N. Silverman

Sector: Healthcare

Employees: 2

Address: 3960 Howard Hughes Parkway, Las Vegas, NV 89169

Phone: 917 595 2850

Leadership

  • Joshua N. Silverman, Independent Director
  • Dr. Michael M. Abecassis, Independent Director
  • Robert Weinstein, Director
  • Wayne R. Walker, Director
  • Jonathan L. Schechter, Independent Director
  • Dr. Abecassis, Director
  • Kenneth L. Waggoner, Independent Director
  • Daniel C. Farb, Independent Director
  • Daniel C. Allen, Independent Director
  • Jack E. Stover, Independent Director

Last updated: 2024-12-31

Arcellx, Inc.

Arcellx, Inc. logo
Market Cap: High
Employees: Low

CART-dd BCMA

Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.

Tags: acute myeloid leukemia, biotechnology, cancer treatment, clinical-stage, immunotherapy, multiple myeloma, myelodysplastic syndrome

Symbol: ACLX

Recent Price: $78.35

Industry: Biotechnology

CEO: Mr. Rami Elghandour

Sector: Healthcare

Employees: 130

Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878

Phone: 240 327 0603

Last updated: 2024-12-31

Celcuity Inc.

Celcuity Inc. logo
Market Cap: Medium
Employees: Lowest

CELsignia diagnostic platform

Celcuity Inc., a biotechnology company, develops targeted therapies for cancer patients in the US, including the CELsignia diagnostic platform and Gedatolisib drug candidate.

Tags: Gedatolisib, HER2-negative, biotechnology, breast cancer, cancer therapy, diagnostic platform

Symbol: CELC

Recent Price: $13.13

Industry: Biotechnology

CEO: Mr. Brian F. Sullivan

Sector: Healthcare

Employees: 55

Address: 16305–36th Avenue North, Minneapolis, MN 55446

Phone: 763 392 0767

Leadership

  • Brian Sullivan, CEO and Co-founder
  • Lance Laing, PhD, Chief Science Officer and Co-founder
  • Vicky Hahne, CFO
  • Igor Gorbatchevsky, MD, Chief Medical Officer
  • Eldon Mayer, Chief Commercial Officer
  • Brent Eilefson, General Counsel
  • Bernhard Lampert, PhD, VP of Pharmaceutical Development
  • Nadene Zack, VP Clinical Operations
  • Sunni Miller, VP of Regulatory Affairs
  • David Bridge, VP of Quality Assurance and Process Development
  • William Strickland, PharmD, VP of Medical Affairs
  • Fred Kerwood, VP of Program Management
  • Charlotte Moser, MD, PhD, SVP of Clinical Development
  • John R. MacDonald, PhD, SVP of R&D
  • Lance Laing, PhD, Chief Science Officer and Co-Founder
  • Richard Buller, MD, PhD, Director
  • David F. Dalvey, Director
  • Leo Furcht, MD, Director
  • Polly Murphy, DVM, PhD, Director
  • Richard J. Nigon, Director

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. logo
Market Cap: High
Employees: Low

therapeutic monoclonal and bispecific antibodies

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.

Tags: biopharmaceutical, bispecific antibodies, cancer treatment, inflammatory diseases, monoclonal antibodies

Symbol: CLDX

Recent Price: $25.12

Industry: Biotechnology

CEO: Mr. Anthony S. Marucci M.B.A.

Sector: Healthcare

Employees: 160

Address: Perryville III Building, Hampton, NJ 08827

Phone: 908 200 7500

Leadership

  • Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
  • Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
  • Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Sam Martin, Senior Vice President and Chief Financial Officer
  • Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
  • Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
  • Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
  • Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
  • Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
  • Keith L. Brownlie, Former Partner, Ernst & Young LLP
  • Herbert J. Conrad, Former President, Roche Pharmaceuticals US
  • James J. Marino, J.D., Former Partner, Dechert LLP
  • Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
  • Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
  • Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
  • Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
  • Carl June, M.D.,
  • Michel Nussenzweig, M.D., Ph.D.,
  • Marc E. Rothenberg M.D., Ph.D.,
  • Joseph Schlessinger, Ph.D.,
  • Louis Weiner, M.D.,

Last updated: 2024-12-31

Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

CLR 131

Cellectar Biosciences, Inc. is a clinical biopharmaceutical company concentrating on the development and commercialization of drugs for cancer treatment.

Tags: biopharmaceutical, cancer treatment, drug development, phospholipid drug conjugate

Symbol: CLRB

Recent Price: $0.29

Industry: Biotechnology

CEO: Mr. James V. Caruso

Sector: Healthcare

Employees: 20

Address: 100 Campus Drive, Florham Park, NJ 07932

Phone: 608 441 8120

Leadership

  • James Caruso, President, CEO and Director
  • Chad Kolean, Chief Financial Officer
  • Shane Lea, Chief Commercial Officer
  • Jarrod Longcor, Chief Operating Officer
  • Andrei Shustov, Senior Vice President, Medical
  • Douglas J. Swirsky, Chairman of the Board
  • Asher Alban Chanan-Khan, MD., Director
  • Frederick W. Driscoll, Director
  • Stefan D. Loren, Ph.D., Director
  • John Neis, Director
  • Cellectar Biosciences, Inc., Company Information

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

Legend Biotech Corporation

Legend Biotech Corporation logo
Market Cap: Highest
Employees: High

LCAR-B38M

Legend Biotech Corporation is a clinical-stage biopharmaceutical company focusing on the discovery and development of novel cell therapies for oncology and other indications globally.

Tags: CAR-T, biopharmaceutical, cell therapy, clinical trials, lymphoma, multiple myeloma, oncology

Symbol: LEGN

Recent Price: $32.77

Industry: Biotechnology

CEO: Dr. Ying Huang Ph.D.

Sector: Healthcare

Employees: 2200

Address: 2101 Cottontail Lane, Somerset, NJ 08873

Phone: 732 317 5050

Leadership

  • Ying Huang, Ph.D., CHIEF EXECUTIVE OFFICER
  • Guowei Fang, Ph.D., CHIEF SCIENTIFIC OFFICER AND HEAD OF BUSINESS DEVELOPMENT
  • Lori Macomber, CHIEF FINANCIAL OFFICER
  • Mythili Koneru, M.D., Ph.D., CHIEF MEDICAL OFFICER
  • Jim Pepin, GENERAL COUNSEL
  • Steve Gavel, SENIOR VICE PRESIDENT, COMMERCIAL DEVELOPMENT, US & EUROPE
  • Yuhong Qiu, Ph.D., SENIOR VICE PRESIDENT, GLOBAL REGULATORY AFFAIRS
  • Birk VanderweeΓ«n, SENIOR VICE PRESIDENT, GLOBAL MANUFACTURING & SUPPLY
  • Alan Kick, SENIOR VICE PRESIDENT, GLOBAL QUALITY
  • Doug Wallace, VICE PRESIDENT, GLOBAL OPERATIONS
  • Elaine Qian, VICE PRESIDENT, GLOBAL HEAD OF HUMAN RESOURCES
  • Tim Roberts, Global Compliance Officer
  • Simon Wu, Senior Vice President, General Manager, Greater China
  • Frank Zhang, EMBA, Ph.D., CHAIRMAN OF THE BOARD, LEGEND BIOTECH
  • Sally Wang, M.S., PRESIDENT, GENSCRIPT
  • Zhu Li, Ph.D., CHIEF STRATEGY OFFICER, GENSCRIPT
  • Corazon (Corsee) Dating Sanders, Ph.D., CO-CHAIR OF THE BOARD OF ADVISORS, FRED HUTCH CANCER CENTER
  • Darren Ji, M.D., Ph.D. and MBA, CHAIRMAN AND CEO, ELPISCIENCE BIOPHARMACEUTICALS
  • Philip Yau, CHIEF FINANCIAL OFFICER. C&J CLARK
  • Patrick Casey, Ph.D., SENIOR VICE DEAN OF RESEARCH, DUKE-NUS MEDICAL SCHOOL SINGAPORE AND A JAMES B. DUKE PROFESSOR OF PHARMACOLOGY AND CANCER BIOLOGY, DUKE UNIVERSITY
  • Tomas J. Heyman, CEO, INTERLAKEN THERAPEUTICS
  • Li Mao, M.D., CHIEF MEDICAL OFFICER, SCICLONE PHARMACEUTICALS
  • Peter Salovey, Ph.D., Chris Argyris Professor of Psychology; Professor of Management, Epidemiology & Public Health, and Sociology; and President Emeritus of Yale University
  • Michel Vounatsos, FORMER CEO OF BIOGEN INC.
  • John Maraganore, Ph.D., FORMER CEO OF ALNYLAM PHARMACEUTICALS

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

Instil Bio, Inc.

Instil Bio, Inc. logo
Market Cap: Low
Employees: Lowest

ITIL-168, ITIL-306

Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.

Tags: TIL, biopharmaceutical, cancer therapy, cell therapy, clinical-stage

Symbol: TIL

Recent Price: $18.99

Industry: Biotechnology

CEO: Mr. Bronson Crouch

Sector: Healthcare

Employees: 49

Address: 3963 Maple Avenue, Dallas, TX 75219

Phone: 972 499 3350

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Vor Biopharma Inc.

Vor Biopharma Inc. logo
Market Cap: Lowest
Employees: Low

VOR33

Vor Biopharma, Inc. is a clinical-stage company focused on developing engineered hematopoietic stem cell (e HSC) therapies for cancer patients, with a leading product, VOR33, in phase 1/2 trials for AML and other hematological malignancies.

Tags: AML, biotechnology, cancer therapies, e HSC, hematopoietic stem cells

Symbol: VOR

Recent Price: $1.19

Industry: Biotechnology

CEO: Dr. Robert Ang M.B.A., M.D., MBBS

Sector: Healthcare

Employees: 168

Address: 100 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 655 6580

Leadership

  • Robert Ang, MBBS, MBA, President and Chief Executive Officer
  • Eyal Attar, MD, Chief Medical Officer
  • Tirtha Chakraborty, PhD, Chief Scientific Officer
  • Han Choi, MD, LLM, Chief Financial Officer
  • John King, MBA, Chief Commercial Officer and Head of Business Development
  • Tania Philipp, Chief People Officer
  • David Phillips, MBA, Senior Vice President, Head of Quality
  • Samir Vattompadam, MS, Senior Vice President, Portfolio Strategy and Program Management
  • Daniella Beckman, Board of Directors
  • David Lubner, Board of Directors
  • Bill Lundberg, MD, Board of Directors
  • Fouad Namouni, MD, Board Of Directors
  • Matthew R. Patterson, Chairman, Board of Directors
  • Josh Resnick, MD, Board of Directors

Last updated: 2024-12-31

Arcus Biosciences, Inc.

Arcus Biosciences, Inc. logo
Market Cap: High
Employees: Medium

Cancer Therapies

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing cancer therapies, with a pipeline including products like Etrumadenant, Zimberelimab, and Domvanalimab among others.

Tags: biopharmaceutical, cancer therapies, clinical trials, oncology

Symbol: RCUS

Recent Price: $14.91

Industry: Biotechnology

CEO: Dr. Terry J. Rosen Ph.D.

Sector: Healthcare

Employees: 577

Address: 3928 Point Eden Way, Hayward, CA 94545

Phone: 510 694 6200

Last updated: 2024-12-31

Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

Imm Celz

Creative Medical Technology Holdings, Inc. is a biotechnology company focusing on using adult stem cell treatments for immunology, urology, orthopedics, and neurology, offering solutions like Caver Stem, Fem Celz, Stem Spine, Imm Celz, and Ova Stem.

Tags: biotechnology, immunology, neurology, orthopedics, stem cell treatments, urology

Symbol: CELZ

Recent Price: $2.34

Industry: Biotechnology

CEO: Mr. Timothy Warbington

Sector: Healthcare

Employees: 4

Address: 211 East Osborn Road, Phoenix, AZ 85012

Phone: 480 399 2822

Last updated: 2024-12-31

Cullinan Oncology, Inc.

Cullinan Oncology, Inc. logo
Market Cap: Medium
Employees: Low

CLN-081

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Their lead candidate, CLN-081, is in a trial for treating non-small cell lung cancer. The company also has several preclinical products targeting various forms of cancer.

Tags: biopharmaceutical, cancer, clinical trials, immuno-oncology, oncology, therapies

Symbol: CGEM

Recent Price: $12.20

Industry: Biotechnology

CEO: Mr. Nadim Ahmed

Sector: Healthcare

Employees: 85

Address: One Main Street, Cambridge, MA 02142

Phone: 617 410 4650

Last updated: 2024-12-31

Galecto, Inc.

Galecto, Inc. logo
Market Cap: Lowest
Employees: Lowest

GB2064

Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.

Tags: biotechnology, cancer, clinical trials, fibrosis, inflammation, pharmaceutical

Symbol: GLTO

Recent Price: $4.60

Industry: Biotechnology

CEO: Dr. Hans T. Schambye M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 75 State Street, Boston, MA 02109

Phone: 457 070 5210

Last updated: 2024-12-31